Catheter Precision, Inc. (VTAK) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Catheter Precision, Inc. on July 27, 2026, covering events occurring on July 30, 2026. The Company, incorporated in Delaware and trading on NYSE American under the symbol VTAK, reported the consummation of a Series C-4 Closing involving the sale of unregistered equity securities.
Key Financial Metrics
- Capital Raised: The Company issued 2,821 shares of Series C-4 Convertible Preferred Stock with a stated value of $1,000 per share.
- Gross Proceeds: Aggregate gross proceeds from the transaction totaled $2,821,000.00.
- Use of Proceeds: Net proceeds are designated for working capital, general corporate purposes, and the redemption of all outstanding Series B Convertible Preferred Stock.
- Transaction Costs: The Company paid customary placement agent fees and expenses to Dawson James Securities, Inc.
Note: This filing does not provide specific data on revenue, operating profit, cash flow, margins, or total debt levels.
Material Changes
The primary material change is the issuance of new equity securities pursuant to the exercise of Additional Investment Rights by Participating Buyers under a Securities Purchase Agreement dated March 9, 2026. This transaction results in the creation of a new class of preferred stock (Series C-4) that ranks senior to Common Stock regarding dividends and liquidation distributions.
Outlook, Risks, and Unusual Items
- Dilution Risk: The conversion of Series C-4 Preferred Stock into Common Stock will result in dilution for existing Common Stock holders.
- Regulatory Status: The securities were issued in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D, exempt from registration requirements. All buyers are accredited investors.
- Corporate Governance: The Company filed a Certificate of Designation with the Delaware Secretary of State to formalize the rights and preferences of the new stock class.
Investor Verification Checklist
- Verify the full text of the Series C-4 Certificate of Designation (Exhibit 3.1) to understand specific conversion rates, dividend rights, and liquidation preferences.
- Confirm the exact amount of net proceeds available after deducting placement agent fees and expenses.
- Review the terms of the outstanding Series B Convertible Preferred Stock to assess the impact of the planned redemption.
- Check the March 9, 2026, Form 8-K for the original Securities Purchase Agreement terms referenced in this filing.